Encompass Clinical Research

1. Eli Lilly and Company $7,239,037 82 payments
2. Merck Sharp & Dohme Corporation $1,182,278 80 payments
3. Sanofi US Services Inc. $927,380 64 payments
4. Novo Nordisk AS $922,092 1,331 payments
5. Novartis Pharmaceuticals Corporation $793,952 12 payments
6. Pfizer Inc. $778,063 74 payments
7. Genentech, Inc. $622,298 42 payments
8. Boehringer Ingelheim Pharmaceuticals, Inc. $420,370 30 payments
9. VIVUS, Inc. $169,875 2 payments
10. Hoffmann-La Roche Limited $149,109 9 payments

1. V503-049 A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20 to 45 years of age $910,006 29 payments
2. A Phase 3B Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 MG in Adults Who Have Obesity Or Overweight With Weight-Related Comorbidities (Surmount-5) $783,798 2 payments
3. A Phase 3B, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 MG in Adults Who Have Obesity Or Overweight With Weight-Related Comorbidities (Surmount-5) $726,781 2 payments
4. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $634,112 39 payments
5. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity $626,428 3 payments
6. A Study of Ly3298176 (Tirzepatide) for the Maintenance of Body Weight Reduction in Participants Who Have Obesity Or Overweight With Weight-Related Comorbidities $614,530 4 payments
7. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $607,359 9 payments
8. A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (Achieve-3) $590,104 4 payments
9. Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity Or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-2) $547,921 5 payments
10. CT-388-104 OW/OB with T2D $405,617 28 payments

1. Other $169,875 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.